Luca Issi
Stock Analyst at RBC Capital
(4.41)
# 351
Out of 5,046 analysts
210
Total ratings
51.18%
Success rate
20.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Luca Issi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Maintains: Outperform | $850 → $860 | $818.50 | +5.07% | 2 | Oct 31, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Outperform | $80 → $82 | $74.30 | +10.36% | 10 | Oct 30, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Sector Perform | $5 → $7 | $8.74 | -19.91% | 2 | Oct 30, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Sector Perform | $21 → $14 | $12.62 | +10.94% | 6 | Oct 28, 2025 | |
| RNA Avidity Biosciences | Downgrades: Sector Perform | $61 → $72 | $69.85 | +3.08% | 3 | Oct 28, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $435 → $500 | $456.04 | +9.64% | 28 | Sep 19, 2025 | |
| RGNX REGENXBIO | Maintains: Outperform | $21 → $17 | $12.77 | +33.12% | 10 | Aug 8, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Outperform | $40 → $38 | $42.39 | -10.36% | 9 | Aug 8, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $210 → $230 | $201.60 | +14.09% | 3 | Aug 8, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Sector Perform | $38 → $42 | $63.99 | -34.36% | 14 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $23 | $22.58 | +1.86% | 3 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $4.30 | -6.98% | 8 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $1.24 | +706.45% | 9 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $21 → $18 | $21.47 | -16.16% | 7 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $32 → $28 | $27.16 | +3.09% | 17 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $20 | $10.01 | +99.80% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $105 → $95 | $40.91 | +132.22% | 7 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $2 | $0.60 | +234.45% | 6 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $11.66 | +45.80% | 1 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $9.08 | +43.17% | 6 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $35 | $11.50 | +204.35% | 7 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $24 → $26 | $25.01 | +3.96% | 7 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $53.57 | +30.67% | 12 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $24 | $67.69 | -64.54% | 6 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $36.06 | +58.07% | 1 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $3.08 | +29.87% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $77 | $34.60 | +122.54% | 3 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $7 → $15 | $9.04 | +65.93% | 5 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $2.42 | +478.51% | 5 | Aug 7, 2024 |
argenx SE
Oct 31, 2025
Maintains: Outperform
Price Target: $850 → $860
Current: $818.50
Upside: +5.07%
Ionis Pharmaceuticals
Oct 30, 2025
Maintains: Outperform
Price Target: $80 → $82
Current: $74.30
Upside: +10.36%
Fulcrum Therapeutics
Oct 30, 2025
Maintains: Sector Perform
Price Target: $5 → $7
Current: $8.74
Upside: -19.91%
Intellia Therapeutics
Oct 28, 2025
Downgrades: Sector Perform
Price Target: $21 → $14
Current: $12.62
Upside: +10.94%
Avidity Biosciences
Oct 28, 2025
Downgrades: Sector Perform
Price Target: $61 → $72
Current: $69.85
Upside: +3.08%
Alnylam Pharmaceuticals
Sep 19, 2025
Maintains: Outperform
Price Target: $435 → $500
Current: $456.04
Upside: +9.64%
REGENXBIO
Aug 8, 2025
Maintains: Outperform
Price Target: $21 → $17
Current: $12.77
Upside: +33.12%
Arrowhead Pharmaceuticals
Aug 8, 2025
Maintains: Outperform
Price Target: $40 → $38
Current: $42.39
Upside: -10.36%
Ascendis Pharma
Aug 8, 2025
Maintains: Outperform
Price Target: $210 → $230
Current: $201.60
Upside: +14.09%
CRISPR Therapeutics AG
Aug 5, 2025
Maintains: Sector Perform
Price Target: $38 → $42
Current: $63.99
Upside: -34.36%
Jul 29, 2025
Maintains: Outperform
Price Target: $25 → $23
Current: $22.58
Upside: +1.86%
May 15, 2025
Maintains: Sector Perform
Price Target: $5 → $4
Current: $4.30
Upside: -6.98%
May 14, 2025
Reiterates: Outperform
Price Target: $10
Current: $1.24
Upside: +706.45%
May 8, 2025
Maintains: Sector Perform
Price Target: $21 → $18
Current: $21.47
Upside: -16.16%
May 2, 2025
Maintains: Sector Perform
Price Target: $32 → $28
Current: $27.16
Upside: +3.09%
Mar 25, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $10.01
Upside: +99.80%
Mar 19, 2025
Maintains: Outperform
Price Target: $105 → $95
Current: $40.91
Upside: +132.22%
Mar 18, 2025
Reiterates: Sector Perform
Price Target: $2
Current: $0.60
Upside: +234.45%
Mar 18, 2025
Initiates: Outperform
Price Target: $17
Current: $11.66
Upside: +45.80%
Mar 17, 2025
Maintains: Outperform
Price Target: $11 → $13
Current: $9.08
Upside: +43.17%
Mar 3, 2025
Maintains: Outperform
Price Target: $39 → $35
Current: $11.50
Upside: +204.35%
Feb 26, 2025
Maintains: Sector Perform
Price Target: $24 → $26
Current: $25.01
Upside: +3.96%
Feb 20, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $53.57
Upside: +30.67%
Jan 21, 2025
Reiterates: Outperform
Price Target: $24
Current: $67.69
Upside: -64.54%
Jan 21, 2025
Reiterates: Outperform
Price Target: $57
Current: $36.06
Upside: +58.07%
Dec 13, 2024
Maintains: Sector Perform
Price Target: $5 → $4
Current: $3.08
Upside: +29.87%
Nov 6, 2024
Reiterates: Outperform
Price Target: $77
Current: $34.60
Upside: +122.54%
Oct 21, 2024
Maintains: Sector Perform
Price Target: $7 → $15
Current: $9.04
Upside: +65.93%
Aug 7, 2024
Reiterates: Outperform
Price Target: $14
Current: $2.42
Upside: +478.51%